BioLineRx to Report Second Quarter 2024 Results on August 15, 2024
BioLineRx (NASDAQ: BLRX), a commercial stage biopharmaceutical company focusing on oncology and rare diseases, will announce its second quarter 2024 financial results on August 15, 2024, before the U.S. markets open.
The company will host a conference call at 8:30 a.m. EDT on the same day, featuring remarks by CEO Philip Serlin. Investors can join the call by dialing +1-888-281-1167 (U.S.) or +972-3-918-0685 (international).
A live webcast and replay of the call will be available on the company's website. The replay can also be accessed by dialing +1-888-295-2634 (U.S.) or +972-3-925-5904 (international) until August 19, 2024.
BioLineRx (NASDAQ: BLRX), un'azienda biofarmaceutica in fase commerciale che si concentra sull'oncologia e sulle malattie rare, annuncerà i suoi risultati finanziari per il secondo trimestre del 2024 il 15 agosto 2024, prima dell'apertura dei mercati statunitensi.
L'azienda terrà una conference call alle 8:30 a.m. EDT lo stesso giorno, con interventi del CEO Philip Serlin. Gli investitori possono partecipare alla chiamata componendo il numero +1-888-281-1167 (USA) o +972-3-918-0685 (internazionale).
Un webcast in diretta e la registrazione della chiamata saranno disponibili sul sito web dell'azienda. La registrazione può essere anche acceduta componendo il numero +1-888-295-2634 (USA) o +972-3-925-5904 (internazionale) fino al 19 agosto 2024.
BioLineRx (NASDAQ: BLRX), una empresa biofarmacéutica en etapa comercial centrada en oncología y enfermedades raras, anunciará sus resultados financieros del segundo trimestre de 2024 el 15 de agosto de 2024, antes de la apertura de los mercados de EE. UU.
La empresa realizará una conferencia telefónica a las 8:30 a.m. EDT el mismo día, con comentarios del CEO Philip Serlin. Los inversores pueden unirse a la llamada marcando +1-888-281-1167 (EE.UU.) o +972-3-918-0685 (internacional).
Habrá un webcast en vivo y una repetición de la llamada que estará disponible en el sitio web de la empresa. La repetición también se puede acceder marcando +1-888-295-2634 (EE.UU.) o +972-3-925-5904 (internacional) hasta el 19 de agosto de 2024.
BioLineRx (NASDAQ: BLRX), 암과 희귀병에 초점을 맞춘 상업 단계의 생명공학 회사는 2024년 2분기 재무 결과를 2024년 8월 15일 미국 시장 개장 전에 발표할 예정입니다.
회사는 동일한 날 오전 8시 30분 EDT에 CEO Philip Serlin의 발언이 포함된 컨퍼런스 콜를 개최합니다. 투자자들은 +1-888-281-1167(미국) 또는 +972-3-918-0685(국제)로 전화하여 콜에 참여할 수 있습니다.
회사의 웹사이트에서 생중계 및 요약을 볼 수 있습니다. 요약은 2024년 8월 19일까지 +1-888-295-2634(미국) 또는 +972-3-925-5904(국제)를 통해 확인할 수 있습니다.
BioLineRx (NASDAQ: BLRX), une entreprise biopharmaceutique en phase commerciale axée sur l'oncologie et les maladies rares, annoncera ses résultats financiers du deuxième trimestre 2024 le 15 août 2024, avant l'ouverture des marchés américains.
L'entreprise organisera une conférence téléphonique à 8h30 EDT le même jour, avec des commentaires du PDG Philip Serlin. Les investisseurs peuvent rejoindre l'appel en composant le +1-888-281-1167 (États-Unis) ou le +972-3-918-0685 (international).
Un webinaire en direct et une rediffusion de l'appel seront disponibles sur le site Web de l'entreprise. La rediffusion peut également être accédée en composant le +1-888-295-2634 (États-Unis) ou le +972-3-925-5904 (international) jusqu'au 19 août 2024.
BioLineRx (NASDAQ: BLRX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf Onkologie und seltene Krankheiten konzentriert, wird am 15. August 2024 vor der Eröffnung der US-Märkte seine Finanzergebnisse für das zweite Quartal 2024 bekannt geben.
Das Unternehmen wird am selben Tag um 8:30 Uhr EDT eine Telefonkonferenz veranstalten, die von CEO Philip Serlin geleitet wird. Investoren können sich unter +1-888-281-1167 (USA) oder +972-3-918-0685 (international) zur Konferenz zuschalten.
Ein Live-Webcast sowie eine Wiederholung der Konferenz werden auf der Website des Unternehmens verfügbar sein. Die Wiederholung kann ebenfalls bis zum 19. August 2024 unter +1-888-295-2634 (USA) oder +972-3-925-5904 (international) abgerufen werden.
- None.
- None.
Management to Hold Conference Call at 8:30 a.m. EDT
The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.
To access the conference call, please dial +1-888-281-1167 from the
About BioLineRx
BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the
Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn. and events.
CONTACTS:
John Lacey
BioLineRx
IR@biolinerx.com
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/2154863/4547338/BioLineRx_Ltd_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-second-quarter-2024-results-on-august-15-2024-302217780.html
SOURCE BioLineRx Ltd.
FAQ
When will BioLineRx report its second quarter 2024 results?
What time is BioLineRx's Q2 2024 earnings conference call?
How can I join BioLineRx's Q2 2024 earnings call?
Will there be a replay available for BioLineRx's Q2 2024 earnings call?
